4 June 2020 - The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees and commentators, clinical experts and patient experts.

Isatuximab in combination with pomalidomide and dexamethasone is not recommended, within its anticipated marketing authorisation, for treating adults with relapsed and refractory multiple myeloma who have had at least 2 treatments (including lenalidomide and a proteasome inhibitor) and whose disease has progressed on the last treatment.

Sanofi has proposed that isatuximab plus pomalidomide and dexamethasone is for treating multiple myeloma only in people who have had at least 3 treatments before. Current treatment at this point is usually pomalidomide plus dexamethasone, or daratumumab alone (in the Cancer Drugs Fund).

Read NICE Appraisal Consultation Document